The use of mycophenolate mofetil (Cellcept®) in enal transplantation

Contributions to Nephrology

Volumn 124, Issue , 1998, Pages 64-75

  Vanrenterghem, Y ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Immunosuppression; Purine synthesis; Rejection; Renal transplantation

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; CASE REPORT; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MALE; REOPERATION; REVIEW;

ADULT; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; REOPERATION;

EID: 0032253515     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (31)

1. Opelz G for the Collaborative Transplant Study: Collaborative Transplant Study - 10-year report. Transplant Proc 1992;24:2342-2355.
2. European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial. Lancet 1983;ii:986-989.
3. Thiel G, Harder F, Lörtscher R, Brünisholz M, Landmann J, Brunner F, Follath F, Wenk M, Mihatsch M: Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Klin Wochenschr 1983;61:991-1000.
4. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH: The impact of acute rejection episodes on long-term graft function and outcome in 1,347 primary renal transplants treated by three cyclosporine regimens. Transplantation 1993;56:307-315.
5. Gulanikar AC, McDonald AS, Sungertekin U, Belitsky P: The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992;53:232-328.
6. Vanrenterghem YFCh: Acute rejection and renal allograft outcome. Nephrol Dial Transplant 1994; 10(suppl 1):29-31.
7. Terasaki PI, Yuge J, Cecka JM, Gjertson DW, Takemoto S, Cho Y: Thirty-year trends in clinical kidney transplantation; in Terasaki PI, Cecka JM (eds): Clinical Transplants 1993. Los Angeles, UCLA Tissue Typing Laboratory, 1994, pp 553-563.
8. Sweeney MJ: Mycophenolic acid and its mechanism of action in cancer and psoriasis. Jpn J Antibiot 1977;30(suppl):85-92.
9. Allison AC, Eugui EM: The design and the development of an immunosuppressive drug, Mycophenolate Mofetil. Springer Semin Immunopathol 1993;14:353-380.
10. Allison AC, Hovi T, Watts RWE, Webster ADB: Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet 1975;ii:1179-1182.
11. Lee WA, Gu L, Kiksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through aminoester derivatization. Pharm Res 1990;7:161-166.
12. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972;32:1803-1809.
13. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-524.
14. Natsumeda Y, Carr SF: Human type I and II IMP dehydrogenases as drug targets. Ann NY Acad Sci 1993;696:88-93.
15. Allison AC, Eugui EM: Preferential suppression of lymphocyte proliferation by mycophenolate acid and predicted long-term effects of Mycophenolate Mofetil in transplantation. Transplant Proc 1994;26:3205-3210.
16. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of Mycophenolate Mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-1325.
17. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: Transplantation 1995;60:225-232.
18. The Tricontinental Mycophenolate Mofetil Renal Transplant Trial Study Group: A blinded, randomized clinical trial of Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-1037.
19. Sollinger HW, Belzer FO, Deierhoi MH, Dietlelm AG, Gonwa TA, Kayffman RS, Klinthalm GB, McDiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443 (Mycophenolate Mofetil): A multicenter study for refractory kidney transplant rejection. Ann Surg 1992;216:513-519.
20. The Mycophenolate Mofetil Renal Refractory Rejection Study Group: Mycophenolate Mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996;61:722-729.
21. Klintmalm GB, Ascher NL, Busuttil RW, Deierhoi M, Gonwa TA, Kauffman R, McDiarmid S, Poplawski S, Sollinger H, Roberts J: RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993;25:679.
22. Kirklin JK, Bourge RC, Naftel DC, Morrow WR, Deierhoi MH, Kauffman RS, White-Williams C, Nombergg RI, Holman WL, Smith DC: Treatment of recurrent heart rejection with Mycophenolate Mofetil (RS-61443): Initial clinical experience. J Heart Lung Transplant 1994;13:444-450.
23. Opelz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;ii:1514-1516.
24. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL: Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985;39:461-472.
25. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL: Effects of RS-61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995;59:460-466.
26. O'Hair DP, McManus RP, Komorowski R: Inhibition of chronic rejection in primate cardiac xenografts using Mycophenolate Mofetil. Ann Thorac Surg 1994;58:1311-1313.
27. Allison AC, Kowalski WJ, Muller CD, Eugui EM: Mechanism of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
28. Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, Mycophenolate Mofetil. Immunol Rev 1993;136:5-28.
29. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC: Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis. Transplant Proc 1990;22:1659-1662.
30. Parker G, Bullingham R, Kamm B, Hale M: Pharmacokinetics of oral Mycophenolate Mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996; 36:332-336.
31. Bullingham R, Monroe S, Nicholls A, Hale M: Pharmacokinetics and bioavailability of Mycophenolate Mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-324.